Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

About jeremiah@devisedesigns.com

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 156 entries already.

Entries by jeremiah@devisedesigns.com

Neurology

A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation.

Hu et al. • 2012 • PLoS One. 2012;7(9):e46224.

August 15, 2012
Neurology

Acute effects of neonatal dexamethasone treatment on proliferation and astrocyte immunoreactivity in hippocampus and corpus callosum: towards a rescue strategy.

Claessens et al. • 2012 • Brain Res. 2012;1482:1-12.

July 15, 2012
Hypercortisolism (Cushing syndrome)

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome.

Fleseriu et al. • 2012 • J Clin Endocrinol Metab. 2012;97(6):2039-49.

April 15, 2012
Oncology

Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues

Melhem et al • 2009 • Clin Cancer Res.

November 15, 2009
Neurology

Slowing the progression of cognitive decline in Alzheimer’s disease using mifepristone.

Belanoff et al. • 2002 • J Mol Neurosci. 2002;19(1-2):201-6.

August 15, 2002
Hypercortisolism (Cushing syndrome)

Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486).

Chu et al. • 2001 • J Clin Endocrinol Metab. 2001;86(8):3568-73.

August 15, 2001
Page 16 of 16«‹141516

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top